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Abstract 
Background: In multiple sclerosis (MS) rehabilitation, most currently used outcome measures were 
validated in patients with a relapsing remitting MS and mild to moderate impairments. We aimed 
to assess whether these measures were also adequate in more impaired patients, frequently 
encountered in those with progressive MS (PMS). 
Methods: Outcome measurements were extracted from medical records of 229 patients with PMS 
undergoing 3 weeks of routine inpatient rehabilitation between 2011 and 2015. We assessed the 
acceptability of Nine-Hole Peg Test (9HPT), Timed 25-Foot Walk (T25FW), 2-Minute Walk Test 
(2MWT), Rivermead Mobility Index (RMI) and the Functional Independence Measure (FIM) by 
analysing their statistical distributions, concurrent validity by comparing Spearman correlations 
with pre-specified hypotheses, and responsiveness across impairment status by calculating 
standardized response means. 
Results: Our concurrent validity hypotheses were mainly satisfied. However, all outcome measures 
had skewed distributions, showed low variability, and thus were inadequately discriminative. 
Moreover, 9HPT was never responsive across the impairment states, whereas the T25FW was 
responsive for mildly impaired patients, and the 2MWT for mild to moderate MS, respectively. 
Generic multi-items measures such as RMI and FIM-motor were adequately responsive for all 
severity levels. 
Conclusions: Currently used outcome measures are inadequate for patients with impaired mobility, 
and there is a dire need of specifically designed outcome measures for routine care that are less 
burdensome and short-term responsive.  
 
Key-words: Neurological Rehabilitation, Progressive Multiple Sclerosis, Outcome Assessment 
(Health Care), performance-based measure, responsiveness, validity 
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Abbreviations: 5STS = 5 repetition Sit-to-Stand test, CI = confidence interval, FIM = Functional 
Independence Measure, FIST  = Function in Sitting Test, MSEDGE = Multiple Sclerosis 
Evaluation Database to Guide Effectiveness, MSOAC  = Multiple Sclerosis Outcome Assessments 
Consortium, MSTF = Multiple Sclerosis Task Force (MSTF), OM = Outcome Measure, PMS = 
Progressive Multiple Sclerosis, RMI = Rivermead Mobility Index, SaGAS10 = Short and Graphic 
Ability Scale-10, SD = Standard Deviation, SRM = Standardized Response Mean. 
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1. Introduction 
 
Multiple sclerosis (MS) is a chronic disease of the Central Nervous System, characterized by a 
variety of manifestations in different functional systems. Due to the limited options for 
immunomodulatory treatment (Elovaara et al., 2018), rehabilitation plays an essential role in 
reducing the multi-faceted MS-caused impairments in persons with progressive MS (PMS). For 
objective and reliable evaluation of rehabilitation interventions, the use of standardized outcome 
measures (OMs) is crucial (Jette DU, Halbert J, 2009). Generally, a comprehensive core set of 
OMs should include feasible, acceptable, valid, and responsive OMs. They should also cover all 
the relevant International Classification of Functioning, Disability and Health (ICF) domains 
(Stucki, 2016), namely activity and participation (Khan et al., 2007).  
 
In response to the multitude of proposed OMs in MS rehabilitation, the American Physical Therapy 
Association Neurology Section nominated the MS Task Force (MSTF) to review and assess the 
psychometric data and clinical utility of the most common OMs in the field. Subsequently, the 
MSTF issued setting and MS-severity specific recommendations for 63 OMs (henceforth 
MSEDGE guidelines) (Potter et al., 2014). Moreover, the MS Outcome Assessments Consortium 
(MSOAC) pursued a similar goal, but with a focus on clinical trials, and aims „to accelerate the 
development of therapies for MS“ (Larocca et al., 2017). 
 
In routine inpatient rehabilitation settings, patient characteristics tend to differ very substantially 
from the general MS population in outpatient clinics and clinical studies, mainly due to a much 
larger proportion of patients with a PMS form. PMS forms are also underrepresented in most 
rehabilitation outcome validation studies, which were mainly performed in patients with relapsing 
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remitting MS (Coleman et al., 2012; Fischer et al., 1999; Gijbels et al., 2012; Kaufman et al., 2000; 
Kragt et al., 2006; Rabadi and Vincent, 2013; Rosti-Otajärvi et al., 2007). The patients with PMS 
have longer disease duration and higher levels of disability that might affect the feasibility as well 
as the psychometric properties of the OMs used in rehabilitation. Precisely to take the effect of 
disability into account, there have also stratified the patients by disability level (Baert et al., 2014). 
Therefore, the aim of this study was to evaluate the psychometric properties of the most commonly 
used OMs in routine rehabilitation for patients with PMS in a routine inpatient rehabilitation 
programme. 
 
2. Methods 
 
2.1 Participants 
 
This study included patients with a PMS form, who underwent an inpatient programme in 2011-
2015 at the Neurorehabilitation Center Berner Klinik Montana. The use of these data was approved 
by the Ethics Committee Zurich (BASEC 2017-00077), who also issued a waiver for the 
retrospective retrieval of informed consent. The Berner Klinik Montana is a neurorehabilitation 
clinic in South-western Switzerland and part of RIMS, the European network for best practice and 
research in MS Rehabilitation. Its MS inpatient rehabilitation programme cares for approximately 
250 patients per year, which corresponds to approximately 35% of all MS neurorehabilitation stays 
in Switzerland. The majority of patients (70%) have a progressive form of MS, either primary or 
secondary. This high percentage can be explained by the reimbursement policies of Swiss 
insurances. 
MS inpatient multidisciplinary rehabilitation consists of a 3-week programme with individualized 
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objectives, consisting of physiotherapy and occupational therapy, complemented with speech 
therapy, nutrition counselling, psychology, neuropsychology, and hippotherapy as needed. The 
therapy sessions are at least 30 minutes long, with a total daily duration of at least 2-3 hours, for at 
least 5 days a week (Khan et al., 2007). 
 
2.2 The measurements 
 
At the Berner Klinik Montana, the OMs assessed, both at baseline and at discharge, are: Functional 
Independence Measure (FIM), Rivermead Mobility Index (RMI), the 2-Minute Walk Test 
(2MWT), and the Timed 25-Foot Walk test (T25FW) assessed by the physiotherapists, and the 
Nine-Hole Peg Test (9HPT) measured by the occupational therapists. The Short and Graphic 
Ability Scale-10 (SaGAS10) is then computed from T25FW and 9HPT (Barin et al., 2016). The 
neurologists assess the Expanded Disability Status Scale (EDSS) only at discharge.  
 
The measurements are performed within 48 hours from admission and at discharge of the patient.  
All OMs used cover the ICF domain of activity, while FIM and EDSS additionally assess the body 
structures and function domain. Moreover, FIM also covers the participation domain. All OMs are 
performance-based and, with the exception of the patient-reported RMI, assessed by health care 
professionals. According to MSEDGE guidelines, T25FW and 9HPT are considered highly 
recommended, while RIM and FIM are recommended, EDSS is not recommended, and 2MWT is 
classified as “unable to recommend” due to lack of evidence at the time of the review. SaGAS10 
was not assessed in MSEDGE guidelines.  
 
2.3 Validation status of the measurements 
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The advantages, but also shortcomings, of these OMs are well documented for the general MS 
population, but have remained largely unexplored in the context of PMS. EDSS is the gold 
standard disability measure in MS (Amato and Portaccio, 2007). However, it has an unequal mean 
stay-time at each progression stage, it is prone to subjectivity, and is poorly responsive in the short-
term (Amato and Portaccio, 2007). The RMI scores 15 mobility tasks with 1 (able to perform) or 0. 
Despite being frequently used for neurological conditions, it has not been validated for MS patients 
(Franchignoni et al., 2003).  
FIM includes 13 motor and five cognitive items that evaluate the independence level in daily 
activities (Skinner and Turner-Stokes, 2006). Its good reliability and concurrent validity were 
demonstrated for MS (Brosseau and Wolfson, 1994), but responsiveness data are limited as 
illustrated by the lack of a Minimal Clinically Important Difference. FIM has been systematically 
collected in the Berner Klinik since 2015 and data were available for 67 patients in our population. 
The 2MWT was recently suggested as a substitute for the gold standard 6-Minute Walk Test (Baert 
et al., 2014; Gijbels et al., 2012). The T25FW at highest safe speed is part of the MS Functional 
Composite (MSFC), and has excellent properties in ambulatory MS patients (Fischer et al., 1999; 
Kaufman et al., 2000). In the Berner Klinik Montana the T25FW test is performed once with a 
flying start (Gijbels et al., 2012), and non-ambulatory patients are scored with a time value of 180 s 
(Hoogervorst et al. 2002). 
9HPT assesses fine manual dexterity and is also a component of the MSFC (Fischer et al., 1999), 
whose properties are well-studied (Kragt et al., 2006). The 9HPT is executed once per hand and, in 
case of failure to complete, 300 s were assigned.(Hoogervorst et al., 2002) For both 9HPT and 
T25FW the standard procedure would require repeating the tasks twice, but, due to time constraints 
and more substantial impairments, it is frequently infeasible in stationary rehabilitation settings. 
SaGAS10 is a revised version of SaGAS (Vaney et al., 2004) and combines logarithmic 
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transformations of right- and left-hand 9HPT, as well as T25FW results. It correlates moderately 
with RMI and EDSS, highly with 2MWT and is moderately responsive (Barin et al., 2016).  
For study inclusion, we required the patients to have a PMS form, and the complete assessments of 
RMI, T25FW, both 9HPTs, and EDSS at discharge. We excluded multiple visits from the same 
patients, including only the first visit, provided the above-mentioned criteria were fulfilled. We 
comprehensively checked the data quality (range checks, missing data), by crosschecking 
suspicious values against patient charts.  
 
2.4 Statistical analysis 
 
We used descriptive statistics to describe the demographic information and baseline assessments. 
We stratified the results by severity level of MS: mild MS when 0≤EDSS≤4, moderate MS when 
4.5≤EDSS≤6.5, and severe MS when EDSS≥7 (Gijbels et al., 2010). 
 
2.4.1 Acceptability 
To assess the acceptability (Fitzpatrick et al., 1998) of the OMs, we investigated the range, mean, 
standard deviation (SD), skewness, and ceiling and floor effects, all at baseline. Ideally, an OM’s 
theoretical range should be fully covered by the observed data; while the empirical distribution 
should be approximately normal (Trochim and Donnelly, 2006), with a skewness index not 
exceeding the absolute value of 2. Furthermore, the fraction of measurements with the lowest or 
highest score should be limited because longitudinal changes may not be detected otherwise. We 
considered ceiling (resp. floor) effects as excellent when the percentage of patients obtaining the 
best (resp. worst) score was ≤5%, adequate when within 5-20%, and poor when ≥20% (Andresen, 
2000; Lim et al., 2008). For interval measures, we applied the following thresholds: ≥11 s for 
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9HPT, ≤240 m for 2MWT, ≥2 s for T25FW. As 9HPT and T25FW are stopped respectively after 5 
and 3 min if not completed, the ceilings were set at 13 s, 2 s, 235 m, the floors at 250 s, 150 s, 5 m, 
for 9HPT, T25FW, and 2MWT respectively. Hence a minimum change of 20% in 9HPT or T25FW 
and of 5 m in 2MWT between rehabilitation entry and discharge could be detected (Baert et al., 
2014; Kragt et al., 2006) . 
 
2.4.2 Concurrent validity 
 
To investigate the cross-sectional concurrent validity, i.e. the concept that OMs truly measure what 
they are supposed to, we followed the approach of McDowell and Jerkinson (McDowell and 
Jenkinson, 1996).  
We first hypothesized expected ranges of correlation coefficients for each pair of OMs (Appendix, 
tables A1, A2, A4), based on their constructs and literature (Brosseau and Wolfson, 1994; Fischer 
et al., 1999; Franchignoni et al., 2003; Gijbels et al., 2012).  
We then calculated Spearman correlation coefficients for each pair of OMs at baseline and checked 
whether they fell within the expected range (and thus indicating good concurrent validity). In 
addition, the strength of the observed correlation was classified as weak (0-0.3), moderate (0.3-
0.5), strong (0.5-0.8), and very strong (0.8-1). 
Since all the OMs are associated with impairment level (EDSS) and disease duration, we checked 
whether, after accounting for these two variables, each pair of OMs were still associated. For this 
analysis we performed partial Spearman correlation on each pair of OMs (table A3) and checked if 
they lay within the predefined correlation ranges (table A2).  
We also assessed the longitudinal concurrent validity. We calculated for each pair of OMs 
Spearman correlation of the differences between baseline and discharge values (tables A5), and 
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then checked if they lay within the predefined correlation ranges (table A4). 
 
2.4.3 Relative Responsiveness 
 
For an OM to detect whether a patient’s status has changed and how, it must assure that it will 
itself change accordingly. This property is called relative responsiveness when more OMs are 
simultaneously assessed, and it was investigated by computing the standardized response mean 
(SRM) (Puhan et al., 2007), with 95% confidence intervals obtained under the assumption of 
normality. We deemed the responsiveness poor if SRM<0.5, adequate when 0.5-0.8, excellent if 
≥0.8 (Cohen, 1977). Pairwise statistical significance of the SRM differences was assessed for all 
possible OM combinations with paired t-test (Puhan et al., 2007). 
All analyses were performed using R v3.3.1 (R foundation, Vienna, Austria). 
 
3. Results 
 
3.1 Participants 
 
There were 920 recorded visits from 467 patients with PMS. Of these visits, 337 fulfilled the 
inclusion criteria, leading to 229 individual patients being included in this study (Figure 1). Tables 
1 and 2 illustrate, respectively, their demographic characteristics and baseline assessments stratified 
by severity level.  
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Figure 1. Sample selection flowchart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
All visits in 2011-2015 
N = 1229 (684 individual patients) 
All visits in 2011-2015 of patients with PMS 
N = 920 (467 individual patients) 
All visits in 2011-2015 of patients with PMS 
and all required assessments at discharge 
N = 337 (229 individual patients) 
All first visits in 2011-2015 of patients with PMS 
and all required assessments at discharge 
N = 229 (229 individual patients) 
Excluded: visits of patients with 
RRMS or undefined MS form 
N = 309 (197 individual patients) 
 
Excluded: visits of patients 
WITHOUT  
RMI, T25FW, 9HPT-R, and 9HPT-L 
at discharge (or reported as 
impossible to perform) 
N = 583 (238 individual patients) 
Excluded:  
multiple visits of patients  
N = 108  
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Table 1. Demographic and MS specific characteristics. 
Results are shown as mean ± standard deviation. SP: secondary progressive; PP: primary 
progressive; P: progressive MS form, not distinguishable between primary and secondary; EDSS: 
Kurtzke’s Expanded Disability Status Scale; Mild MS: 0-4 EDSS; Moderate MS: 4.5-6.5 EDSS; 
Severe MS: 7-10 EDSS. 
  
  
MS subgroups 
Variable Total MS Mild MS Moderate MS 
 
Severe MS 
Size (n) 229 24 132 73 
Age 57.1 ± 11.9 51.3 ± 14.6 58.0 ± 11.4 57.6 ± 11.3 
Gender F, n (%) 148 (64.6%) 18 (75.0%) 85 (64.4%) 45 (61.6%) 
Years since 
diagnosis 
18.6 ± 9.7 16.6 ± 13.2 18.1 ± 9.3 20.3 ± 9.0 
MS form:      
   SP, n (%) 197 (86.0%) 21 (87.5%) 112 (84.8%) 64 (87.7%) 
   PP, n (%) 27 (11.8%) 3 (12.5%) 17 (12.9%) 7 (9.6%) 
   P, n (%) 5 (2.2%) 0 (0%) 3 (2.3%) 2 (2.7%) 
Length of stay in 
days 
21.7 ± 7.8 21.7 ± 4.0 20.8 ± 4.6 23.4 ± 12.1 
EDSS 6.2 ± 1.3 3.5 ± 0.5 6 ± 0.6 7.5 ± 0.5 
Residence:      
   German-speaking  
Switzerland,  
n (%) 
121 (52.8%) 13 (54.2%) 67 (50.8%) 41 (56.1%) 
   French-speaking 
Switzerland,  
n (%) 
107 (46.7%) 11 (45.8%) 65 (49.2%) 31 (42.5%) 
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Table 2. Baseline clinical assessments: mobility and cognitive measures.  
 
 
 
 
 
 
 
 
 
 
Results are shown as median (interquartile range). 
Mild MS: 0-4 EDSS; Moderate MS: 4.5-6.5 EDSS; Severe MS: 7-10 EDSS; RMI: Rivermead 
Mobility Index; FIM-mot: Functional Independence Measure motor subscale; FIM-cog: Functional 
Independence Measure cognitive subscale; 2MWT: 2-Minute Walk Test; T25FW: Timed 25-Foot 
Walk; 9HPT-R: Nine-Hole Peg Test-Right hand; 9HPT-L: Nine-Hole Peg Test-Left hand; 
SaGAS10: Short and Graphic Ability Score 10. 
* FIM available for n=4; 40; and 23 patients with mild; moderate; and severe MS; respectively. 
 
 3.2 Acceptability 
 
In table 3 the distributional characteristics of each OM are illustrated. Observed data covered 
theoretical ranges well for RMI, 2MWT, and the 9HPTs, whereas other OMs only partially covered 
their full range, likely owing to our study focus on more severely disabled patients. Except for RMI 
scores, all other OMs displayed highly skewed distributions with means shifted towards worse 
  
MS subgroups 
Variable 
Total MS Mild MS Moderate MS Severe MS 
Size (n) 229 24 132 73 
RMI 9.0 (4.0-12.0) 13.0 (12.0-14.0) 10.0 (8.0-12.0) 2.5 (1.0-5.0) 
FIM-mot* 75.0 (69.5-80.0) 82.5 (79.8-85.3) 76.0 (73.5-79.0) 70.0 (53.5-78.0) 
FIM-cog* 30.0 (27.0-33.0) 32.5 (32.0-33.5) 31.0 (27.8-33.0) 29.0 (24.5-31.0) 
2MWT (m) 44.0 (0-83.0) 130.0 (90.0-159.0) 60.0 (37.0-87.0) 0 (0-0) 
T25FW (s) 18.0 (10.2-180.0) 7.0 (5.0-11.0) 13.9 (9.0-21.0) 180 (180.0-180.0) 
9HPT-R (s) 33.0 (26.0-46.0) 24.5 (23.0-28.8) 29.0 (25.0-38.0) 46.0 (37.0-79.0) 
9HPT-L (s) 36 (28.0-48.8) 28 (25.3-37.8) 31 (27.0-41.0) 46 (38.0-73.5) 
SaGAS10 2.5 (1.2-4.3) 5.5 (3.7-6.2) 3.4 (2.2-4.5) 1.2 (0.8-1.6) 
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scores (e.g. the 2MWT with a mean of 52 m and a midpoint of 120 m). In terms of floor and ceiling 
effects, the EDSS performed well, whereas FIM-mot, SaGAS10, and 9HPT-R had only adequate 
floor and ceiling effects. While walk tests generally performed well with respect to ceiling effects, 
they performed poorly on floor effects, owing to the inclusion of non-ambulatory patients. 
 
Table 3. Outcome measures distribution features. 
 
Coverage Distribution Floor/ceiling effects 
Variable N 
(over 
229) 
Scale 
range 
Actual 
range 
Mean SD Skewness Floor effects 
(worst score) 
Ceiling effects 
(best score) 
EDSS 229 0-10 2.5-8.5 6.2 1.3 -0.7 0% 0% 
RMI 224 0-15 0-15 8.0 4.5 -0.4 5.8% 1.8% 
FIM-mot 67 13-91 23-91 72.0 13.4 -2.0 0% 1.5% 
FIM-cog 67 5-35 11-35 29.1 5.2 -1.5 0% 10% 
2MWT (m) 209 0-240 0-225 52.0 50.4 0.9 28.7% 0% 
T25FW (s) 216 2-180 3.5-180 62.2 73.4 0.9 26.9% 0% 
9HPT-R (s) 214 11-300 15-303 49.2 53.4 3.7 3.3% 0% 
9HPT-L (s) 214 11-300 12-300 54.9 63.6 4.4 5.1% 0.9% 
SAGAS10 201 0-10 0-6.8 2.8 1.8 0.5 3.9% 0% 
The cells highlighted represent the fields where each OM is not adequate. 
SD: Standard Deviation; EDSS: Kurtzke’s Expanded Disability Status Scale; RMI: Rivermead 
Mobility Index; FIM-mot: Functional Independence Measure motor subscale; FIM-cog: Functional 
Independence Measure cognitive subscale; 2MWT: 2-Minute Walk Test; T25FW: Timed 25-Foot 
Walk; 9HPT-R: Nine-Hole Peg Test-Right hand; 9HPT-L: Nine-Hole Peg Test-Left hand; 
SaGAS10: Short and Graphic Ability Score 10. 
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3.3 Concurrent validity 
 
Table 4 illustrates cross-sectional correlation coefficients and whether their absolute values lie 
within our pre-specified ranges (table A1 of the Appendix). 9HPT-L is not reported because of its 
similarity to 9HPT-R. Both in the total sample and in the severe subgroup the hand dexterity tests 
correlate strongly (ρ=0.63 and ρ=0.70, respectively). 
 
Table 4. Cross-sectional concurrent validity: Spearman correlation. 
Sample Outcome 
measure 
SaGA
S10 
RMI FIM-
mot 
FIM-
cog 
2MWT T25FW 9HPT-R 
 EDSS -0.75 -0.84 -0.45 -0.43 -0.84 0.82 0.49 
 SaGAS10 1 0.79 0.50 0.48 0.88 -0.69 -0.70 
Total RMI  1 0.56 0.43 0.87 -0.84 -0.55 
MS FIM-mot   1 0.65 0.54 -0.48 -0.45 
 FIM-cog    1 0.52 -0.49 -0.34  
 2MWT     1 -0.96 -0.55 
 T25FW      1 0.54 
 EDSS -0.19 -0.55 -0.36 -0.37 -0.55 0.59 0.17 
 SaGAS10 1 0.45 0.35 -0.05 0.31 -0.37 -0.81 
Severe RMI  1 0.54 0.32 0.66 -0.68 -0.36 
MS FIM-mot   1 0.63 0.45 -0.27 -0.42 
 FIM-cog    1 0.41 -0.22 -0.11 
 2MWT     1 -0.95 -0.23 
 T25FW      1 0.17 
The correlations written in bold were within the hypothesized ranges.  
EDSS: Kurtzke’s Expanded Disability Status Scale; SaGAS10: Short and Graphic Ability Score 
10; RMI: Rivermead Mobility Index; FIM-mot: Functional Independence Measure motor subscale; 
FIM-cog: Functional Independence Measure cognitive subscale; 2MWT: 2-Minute Walk Test; 
T25FW: Timed 25-Foot Walk; 9HPT-R: Nine-Hole Peg Test-Right hand; 9HPT-L: Nine-Hole Peg 
Test-Left hand; Severe MS: 7-10 EDSS. 9HPT-L is not reported, because of its similarity to 9HPT-
R. 
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With some exceptions (RMI, T25FW and 9HPT-R), the a priori hypotheses of construct 
correlations were satisfied in the total sample. However, T25FW exhibited unexpectedly strong 
correlations with RMI and 2MWT. For instance, the correlation of T25FW and 2MWT was 
hypothesized to lie between -0.8 and -0.5 but instead was -0.92. RMI correlates strongly instead of 
moderately (as expected) with FIM-mot and 9HPT-R, and very strongly instead of strongly 
(expectation) with the walk tests. Surprisingly, 9HPT-R exhibited moderate to strong correlations 
with all other OMs, which do not assess upper-body mobility. It is known that 9HPT and the 
walking tests depend on the MS severity level (Fischer et al., 1999), so we performed partial 
correlation analysis adjusted for EDSS level and disease duration. We found all partial correlations 
were within the hypothesized ranges (table A2-A3 in the Appendix).  
Looking at differences between baseline and discharge measurements, most OMs also showed 
correlation coefficients in the hypothesized ranges (tables A4-A5 in the Appendix). 
 
3.4 Relative responsiveness 
 
In figure 2 the SRM values with 95% confidence interval (CI) are illustrated, stratified by severity 
level. Table A6 shows the paired t-tests per severity level of the SRM differences for each pair of 
OMs. 
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Figure 2. Standardized Response Mean with 95% CI.  
(single column fitting image, colour only online) 
 
The dotted horizontal line at 0.5 represents the threshold for the SRM to be adequate. 
Mild MS: 0-4 EDSS; Moderate MS: 4.5-6.5 EDSS; Severe MS: 7-10 EDSS; SaGAS10: Short and 
Graphic Ability Score 10; RMI: Rivermead Mobility Index; T25FW: Timed 25-Foot Walk; 
2MWT: 2-Minute Walk Test; 9HPT-R: Nine-Hole Peg Test-Right hand; 9HPT-L: Nine-Hole Peg 
Test-Left hand; FIM-mot: Functional Independence Measure motor subscale; FIM-cog: Functional 
Independence Measure cognitive subscale.  
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The SRM behaves quite differently according to severity level. In the mild group, RMI, SaGAS10 
and the walk tests have an excellent responsiveness, but they are all comparable (as indicated by 
the overlapping confidence intervals in figure 2). By comparison, the 9HPTs have a poor-to-
moderate responsiveness.  
In the moderate disease severity group SaGAS10, RMI, 2MWT, and FIM-mot all have an equally 
moderate to excellent responsiveness, whereas T25FW, 9HPTs and FIM-cog are only poorly 
responsive.  
In the severe subgroup, all the walk-related tests further lose their responsiveness. The 9HPTs 
remain poorly responsive, whereas RMI and FIM-mot achieve a moderate responsiveness. 
 
4. Discussion 
 
In this study we retrospectively analyzed OMs for 229 patients with PMS who underwent inpatient 
rehabilitation in an established, specialized clinic. Our analysis revealed that the gold standard 
OMs in MS rehabilitation such as 9HPT and T25FW (Potter et al., 2014) fail to be adequate in a 
group of persons with PMS from routine care with more severe mobility impairments than usually 
seen in other very selected study populations, and when the follow up time is less than a month. 
First, there were substantial percentages of persons who were unable to perform some tasks. 
Second, in terms of responsiveness the OMs performed particularly poorly among persons with 
moderate and severe MS. By contrast, up to an EDSS of 6.5 the 2MWT demonstrated a better 
responsiveness, but it was not feasible for most persons with severe MS, resulting in a floor effect. 
Additionally, 2MWT had a very skewed distribution and exhibited only a small within-sample 
variability. For persons with severe mobility impairments (EDSS ≥7) the only responsive measures 
were RMI and FIM-mot, which encompass more body functioning dimensions. However, RMI and 
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FIM-mot are generic measures and showed problematic tendencies in our analysis in terms of 
substantial floor effects and very skewed distributions. 
 
PMS is increasingly the focus of international efforts such as the Progressive MS Alliance, that 
aims at accelerating the development and approval process of treatments for PMS types (Zaratin et 
al., 2016). Persons with more severe impairments (such as patients with PMS) are rarely 
represented in validation studies, thus questioning the application of standard OMs as endpoints in 
treatment evaluations for PMS.  
To our knowledge, this is the first validation study to specifically look at OM performance in 
persons with PMS. Nonetheless, our study results are in line with clinical trials involving less 
impaired patients. For instance, Baert and colleagues showed in a multicentre study that long 
walking tests, such as 2MWT, are more responsive than short ones, (e.g. the T25FW) (Baert et al., 
2014). Interestingly, our finding of a limited responsiveness of 9HPT is challenged by a more 
positive evaluation of 9HPT in a recent Ocrelizumab trial (Montalban et al., 2017) or the 
Methotrexate trial (Goodkin et al., 1995), but may be explained by the much longer follow-up 
period between measurements of at least 3 years instead of 3 weeks as in our study. 
 
Recently, there were several publications on novel OMs for persons with severe MS. For example, 
Sung et al. published a validation study of the Function In Sitting Test (FIST), which is a measure 
of sitting balance that is specifically designed for non-ambulatory MS patients (Sung et al., 2016). 
In addition, the 5 repetition Sit-to-Stand test (5-STS) was shown to be valid for MS patients with 
EDSS <7, but its feasibility for non-ambulatory patients remains unclear (Møller et al., 2012).  
 
4.1 Implications on practice  
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When considering only a moderate to severely impaired population with MS (as frequently 
observed in the group of persons with PMS), the OMs already validated for MS do not show the 
expected properties of acceptability and responsiveness.  
Based on our results, we suggest the use of 2MWT, as well as FIM-mot and RMI up to moderate 
MS. Moreover, other potentially interesting OMs, namely the FIST and the 5-STS, could be well 
suited for severe MS (Møller et al., 2012; Sung et al., 2016). In addition, to better identify therapy 
responders, one could include in the core set MS-specific, patient-reported outcomes, such as 
MSIS-29 (Hobart et al., 2001) and MSQoL-54 (Vickrey et al., 1995). However, time restrictions 
may pose an obstacle for implementation in routine care, particularly if they need to be 
administered via interview due to disability severity.  
 
4.2 Study limitations 
 
The present study has evident limitations. First, it is a retrospective analysis of routine OM data.  
Additionally, requiring data completeness might have affected the sample representativeness. For 
this reason our inclusion criteria were kept to a necessary minimum. 
Moreover, a preferable approach to prove responsiveness would be to employ anchor-based 
methods. Due to the lack of a suitable external clinical endpoint or a patient-rated improvement 
measure as an anchor, we took a distribution-based approach. 
In addition, we did not distinguish between patients with primary and secondary progressive MS in 
our analysis. It is not clear whether considering them separately would have had an effect on the 
OMs’ properties (Campbell et al., 2016).  
Finally, it would have been worth exploring the test-retest reliability for the OMs assessed, but no 
data was collected in that regard. 
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Nevertheless, this study represents the first attempt in PMS to simultaneously compare 
rehabilitation OMs. To our knowledge, our study is among the largest for validation studies in MS.  
 
4.3 Conclusion  
In summary, our results highlight further potential for improvement in routine neurorehabilitation 
assessments, particularly for patients with moderate to severe mobility impairment, which is 
frequently encountered among persons with a progressive form. Our findings stress the need for 
OMs that are specifically developed and validated for persons with more severe MS, as the 
majority of currently recommended measures exhibited inadequate measurements characteristics.  
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